AR038924A1 - Utilizacion del acido 6-[3-(1-adamantil)-4-metoxifenil)-2-naftoico para el tratamiento de desordenes dermatologicos - Google Patents
Utilizacion del acido 6-[3-(1-adamantil)-4-metoxifenil)-2-naftoico para el tratamiento de desordenes dermatologicosInfo
- Publication number
- AR038924A1 AR038924A1 ARP030100823A ARP030100823A AR038924A1 AR 038924 A1 AR038924 A1 AR 038924A1 AR P030100823 A ARP030100823 A AR P030100823A AR P030100823 A ARP030100823 A AR P030100823A AR 038924 A1 AR038924 A1 AR 038924A1
- Authority
- AR
- Argentina
- Prior art keywords
- adapalene
- treatment
- inflammatory
- pharmaceutical composition
- weight
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Utilización del ácido 6-[3-(1-adamantil)-4-metoxifenil]-2-naftanoico (adapaleno) o de sus sales para la fabricación de una composición farmacéutica destinada al tratamiento de las afecciones dermatológicas de componente inflamatorio o proliferativo que comprende 0,3% de peso de adapaleno con respecto al peso total de la composición. Reivindicación 1: Utilización del ácido 6-[3-(1-adamantil)-4-metoxifenil]-2-naftanoico (adapaleno) o de sus sales para la fabricación de una composición farmacéutica destinada al tratamiento de las afecciones dermatológicas de componente inflamatorio o proliferativo elegidas entre los acnés vulgares, comedonianos, polimorfos, los acnés noduloquísticos, conglobata, los acnés secundarios tales como el acné solar, medicamentoso o profesional, las formas extendidas y/o severas de psoriasis, las ictiosis y los estados ictiosiformes, la enfermedad de Darier, las queratodermias palmoplantares y la queratosis pilar, y las pigmentaciones postinflamatorias, caracterizada porque la composición farmacéutica comprende 0,3% de peso de adapaleno con respecto al peso total de la composición. Reivindicación 7: Composición farmacéutica que comprende, en un medio fisiológicamente aceptable, ácido 6-[3-(1-adamantil)-4-metoxifenil]-2-naftanoico (adapaleno) o de sus sales destinada al tratamiento de las afecciones dermatológicas de componente inflamatorio proliferativo caracterizada porque comprende 0,3% de peso de adapaleno con respecto al peso total de la composición.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0203070A FR2837101B1 (fr) | 2002-03-12 | 2002-03-12 | Utilisation de l'acide 6-[1-adamantyl)-4-methoxyphenyl]-2- naphthoique pour le traitement de desordres dermatologiques |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR038924A1 true AR038924A1 (es) | 2005-02-02 |
Family
ID=27772059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030100823A AR038924A1 (es) | 2002-03-12 | 2003-03-11 | Utilizacion del acido 6-[3-(1-adamantil)-4-metoxifenil)-2-naftoico para el tratamiento de desordenes dermatologicos |
Country Status (4)
| Country | Link |
|---|---|
| KR (1) | KR101007161B1 (es) |
| AR (1) | AR038924A1 (es) |
| FR (1) | FR2837101B1 (es) |
| ZA (1) | ZA200405853B (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100798853B1 (ko) * | 2005-02-15 | 2008-01-28 | (주)한국스티펠 | 레티노이드를 유효성분으로 하는 백반증 예방 및 치료용 약학적 조성물 |
| FR2901701B1 (fr) * | 2006-05-31 | 2010-10-29 | Galderma Res & Dev | Compostions comprenant au moins un derive de l'acide naphtoique et au moins un agent filmogene, leurs procedes de preparation, et leurs utilisations |
| FR2903603B1 (fr) | 2006-07-13 | 2009-03-20 | Galderma Res & Dev S N C Snc | Combinaison d'adapalene et de peroxyde de benzole dans le traitement de l'acne |
| EP2097075A1 (fr) * | 2006-11-20 | 2009-09-09 | Galderma Research & Development, S.N.C. | Utilisation d'adapalène pour moduler l'expression de cd1d ou il-10. |
| WO2008062135A1 (fr) * | 2006-11-20 | 2008-05-29 | Galderma Research & Development | Utilisation d'adapalène pour moduler l'expression de l'il-1ra. |
| EP2533776A1 (en) | 2010-02-09 | 2012-12-19 | Galderma Research & Development | A dermatological composition comprising a combination of adapalene and benzoyl peroxide for the treatment of acne in non- caucasian population with decrease of post- inflammatory hyperpigmentation |
| CA2796412A1 (en) | 2010-04-29 | 2011-11-03 | Galderma Research & Development | Method for treating scars with adapalene 0.3% |
| JP2015517559A (ja) | 2012-05-25 | 2015-06-22 | ガルデルマ・リサーチ・アンド・デヴェロップメント | 思春期前中程度の尋常性ざ瘡の治療 |
| EP3220903A1 (fr) * | 2014-11-20 | 2017-09-27 | Galderma S.A. | Compositions comprenant un compose de la famille des avermectines et un compose agoniste d'au moins un des recepteurs de l'acide retinoique pour le traitement de l'acne |
| KR102486502B1 (ko) * | 2015-09-15 | 2023-01-09 | 주식회사 엘지생활건강 | 여드름 치료제 전달을 위한 용해성 미세바늘 패치 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LU85849A1 (fr) * | 1985-04-11 | 1986-11-05 | Cird | Derives benzonaphtaleniques,leur procede de preparation et leur application dans les domaines pharmaceutiques et cosmetiques |
| FR2730930B1 (fr) * | 1995-02-27 | 1997-04-04 | Oreal | Utilisation d'inhibiteurs de no-synthase pour diminuer l'effet irritant cutane de produits utilises dans le domaine cosmetique ou pharmaceutique |
-
2002
- 2002-03-12 FR FR0203070A patent/FR2837101B1/fr not_active Expired - Fee Related
-
2003
- 2003-03-11 AR ARP030100823A patent/AR038924A1/es not_active Application Discontinuation
- 2003-03-12 KR KR1020047014228A patent/KR101007161B1/ko not_active Expired - Lifetime
-
2004
- 2004-07-22 ZA ZA200405853A patent/ZA200405853B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR101007161B1 (ko) | 2011-01-12 |
| ZA200405853B (en) | 2008-10-29 |
| KR20040111394A (ko) | 2004-12-31 |
| FR2837101B1 (fr) | 2004-07-02 |
| FR2837101A1 (fr) | 2003-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2450035T3 (en) | Combination of adapalene and benzoyl peroxide for the treatment of acne lesions | |
| NI202100009A (es) | Métodos para reducir la necesidad de revascu | |
| ES2602986T3 (es) | Nuevas composiciones cosméticas y/o farmacológicas y sus aplicaciones | |
| PT1485080E (pt) | Utilização de adapaleno para o tratamento de desordens dermatológicas | |
| AR038924A1 (es) | Utilizacion del acido 6-[3-(1-adamantil)-4-metoxifenil)-2-naftoico para el tratamiento de desordenes dermatologicos | |
| AR124134A2 (es) | Formulación de uso tópico para un inhibidor de jak | |
| NZ600167A (en) | Concentrated therapeutic phospholipid compositions | |
| BR112014031837A2 (pt) | formulações de progesterona | |
| AR065704A1 (es) | Composiciones y equipos para el tratamiento de la influenza | |
| RU2007101519A (ru) | Композиция в форме спрея, содержащая в масляной фазе сочетание кортикоида и производного витамина d | |
| ECSP10010665A (es) | Formulaciones orales de análogos de citidina y métodos para usar los mismos | |
| CL2011003094A1 (es) | Composicion farmaceutica semi-solida libre de agua que comprende a) un ester del acido 5-aminolevulinico (5-ala) o una sal del mismo, b) uno o mas trigliceridos y c) opcionalmente uno o mas potenciadores de viscosidad; kit farmaceutico; y su uso en el tratamiento fotodinamico del cancer, condiciones pre-cancerosas y no cancerosas asociadas a hpv. | |
| CR9626A (es) | Formas de dosificacion de liberacion retardada oral altamente biodisponible de un o-desmetilvenlafaxin succinato | |
| CO6300927A2 (es) | Sales de arginina y un cation, productos de cuidado oral y personal que los contienen y metodos para preparar dichas sales y productos | |
| AR045504A1 (es) | Composicion de ester ramificado | |
| HN2008001771A (es) | Esteres de dha | |
| US20140031427A1 (en) | Combinations of adapalene and benzoyl peroxide for treating acne lesions | |
| NZ601001A (en) | Pharmaceutical composition comprising solvent mixture and a vitamin d derivative or analogue | |
| BR0318343A (pt) | composição tópica para administração transdérmica | |
| CL2010001566A1 (es) | Compuesto derivado de piperidinilo, modulador de la actividad de los receptores de la quimiocina; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades inflamatorias, alergicas, autoinmune. | |
| CY1117801T1 (el) | Μασκα απολεπισης προσωπου απο πολυβινυλιο για τη θεραπευτικη αντιμετωπιση δερματικων παθησεων η οποια περιλαμβανει υψηλη συγκεντρωση ρητινοϊκου οξεος | |
| AR065085A1 (es) | Metodo para tratamiento prolongado del acne vulgaris | |
| AR094035A1 (es) | Estimulantes del colageno y su uso en el tratamiento de la piel | |
| AR056018A1 (es) | Una composicion para usar en la piel | |
| AR054361A1 (es) | Uso de acido adamantil metoxidifenil propenoico para el tratamiento de enfermedades dermatologicas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |